If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Humalog Summary of Product Characteristics (SmPC)
pharmacokinetics of insulin lispro reflect a compound that is rapidly
absorbed, and achieves peak blood levels 30 to 70 minutes
following subcutaneous injection. When considering the clinical
relevance of these kinetics, it is more appropriate to examine the
glucose utilisation curves.
lispro maintains more rapid absorption when compared to soluble human
insulin in patients with renal impairment. In patients with type 2
diabetes over a wide range of renal function the pharmacokinetic
differences between insulin lispro and soluble human insulin were
generally maintained and shown to be independent of renal function.
Insulin lispro maintains more rapid absorption and elimination when
compared to soluble human insulin in patients with hepatic
lispro 200 units/ml solution for injection was bioequivalent to
insulin lispro 100 units/ml solution for injection after
subcutaneous administration of a single 20 unit dose in healthy
subjects. Time to maximum concentration was also similar between
200 Units/ml [Summary of Product Characteristics]. Utrecht, The
Netherlands: Eli Lilly Nederland B.V.
Date of Last Review:December 26, 2018
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org